Nature

Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects

The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously ...
Nature

Effect of the cardiac long non-coding RNA Charme depletion on the maturation and paracrine signaling of resident cardiac fibroblasts

Fig. 1: Charme KO cardiac stroma has reduced expression of ECM synthesis and organization genes, reflected in cardiac tissue decreased collagen I content. The alternative text for this image may have ...
Medical Xpress

In the genetics of congenital heart disease, noncoding DNA fills in some blanks

Researchers have been chipping away at the genetic causes of congenital heart disease (CHD) for a couple of decades. About 45% of cases of CHD have an identifiable cause, including chromosomal ...
Business Wire

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial ...

HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced ...
Nasdaq

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA, July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira Therapeutics ...
BioWorld

AMA panel eyes CPT code for cardiac contractility modulation

The American Medical Association’s CPT editorial panel will meet May 1-3 to consider codes for several devices and services, but the most important of these might be the code for cardiac contractility ...